SALT LAKE CITY, UT--(Marketwired - Mar 17, 2015) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announced it has completed the development of a hospital unit to deliver and monitor Inhaled Nitric Oxide for use in Adults, Pediatrics and Neonates who are on a ventilator in a hospital setting under close medical supervision. It is designed to be modest and instinctive to use.

Nitric oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy and may have future applications for a variety of other diseases and complications that are currently being investigated. Jeff Robins, President and CEO of Nu-Med Plus, Inc. commented, "We are excited to have completed our conversion technology that allows us to produce NO from small amounts of our proprietary powder which may well significantly reduce the existing high cost of NO making it an available and affordable treatment for complications requiring NO gas."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more company information please visit

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Contact Information:

Jeff Robins